Marina Biotech Acquires RNA Delivery Assets of Novosom AG

The transaction further expands Marina's RNA delivery platform IP estate, which now includes DiLA2 delivery platform, tkRNAi (bacterial delivery platform), peptide nanoparticle delivery platform, and the SMARTICLES liposomal delivery platform.

Related Posts

Comments are closed.